A 12-week Randomized Study to Evaluate Oral Istradefylline in Subjects With Moderate to Severe Parkinson's Disease

NCT01968031 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

613

Enrollment

INDUSTRY

Sponsor class

Conditions

Idiopathic Parkinson's Disease

Interventions

DRUG: Istradefylline 40 mg
DRUG: Istradefylline 20 mg
DRUG: Placebo

Sponsor

Kyowa Kirin Co., Ltd.

Collaborators

[object Object]